Darzalex Extends Time to Disease Progression, Death Among Newly Diagnosed Multiple Myeloma Patients, Phase 3 Trial Shows
Multiple myeloma patients who are not eligible for high-dose chemotherapy and stem cell transplant significantly benefit from the addition of Darzalex (daratumumab) to the standard…